MX2017010567A - Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2. - Google Patents
Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2.Info
- Publication number
- MX2017010567A MX2017010567A MX2017010567A MX2017010567A MX2017010567A MX 2017010567 A MX2017010567 A MX 2017010567A MX 2017010567 A MX2017010567 A MX 2017010567A MX 2017010567 A MX2017010567 A MX 2017010567A MX 2017010567 A MX2017010567 A MX 2017010567A
- Authority
- MX
- Mexico
- Prior art keywords
- dimethoxyphenyl
- inhibitors
- monoamine transporter
- vesicular monoamine
- vesicular
- Prior art date
Links
- 125000005805 dimethoxy phenyl group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 title 1
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117654P | 2015-02-18 | 2015-02-18 | |
| PCT/US2016/018222 WO2016133989A1 (en) | 2015-02-18 | 2016-02-17 | Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010567A true MX2017010567A (es) | 2018-03-16 |
Family
ID=56692737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010567A MX2017010567A (es) | 2015-02-18 | 2016-02-17 | Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10722479B2 (enExample) |
| EP (1) | EP3258926A4 (enExample) |
| JP (1) | JP2018507210A (enExample) |
| AR (1) | AR103728A1 (enExample) |
| BR (1) | BR112017017673A2 (enExample) |
| CA (1) | CA2976229A1 (enExample) |
| EA (1) | EA201791839A1 (enExample) |
| IL (1) | IL253901A0 (enExample) |
| MA (1) | MA41557A (enExample) |
| MX (1) | MX2017010567A (enExample) |
| TW (1) | TW201630871A (enExample) |
| WO (1) | WO2016133989A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA852843B (en) | 1984-05-15 | 1985-11-27 | Warner Lambert Co | Bevantolol preparation |
| WO2007139923A1 (en) * | 2006-05-26 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Deuterated aminoglycidyl compounds |
| US20080261926A1 (en) | 2007-04-02 | 2008-10-23 | Liu Julie F | Pharmaceutical Calcimimetics |
| US20100009950A1 (en) * | 2008-06-30 | 2010-01-14 | Auspex Pharmaceuticals, Inc. | Substituted ethanolamines |
| EP3345905B1 (en) * | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US20100143287A1 (en) | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Trifluoromethylphenyl modulators of calcium-sensing receptor |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. | 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| RU2685502C2 (ru) | 2013-06-19 | 2019-04-19 | Сом Инновейшен Биотех, С.Л. | Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств |
-
2016
- 2016-02-16 MA MA041557A patent/MA41557A/fr unknown
- 2016-02-17 WO PCT/US2016/018222 patent/WO2016133989A1/en not_active Ceased
- 2016-02-17 MX MX2017010567A patent/MX2017010567A/es unknown
- 2016-02-17 JP JP2017543828A patent/JP2018507210A/ja active Pending
- 2016-02-17 BR BR112017017673A patent/BR112017017673A2/pt not_active Application Discontinuation
- 2016-02-17 EA EA201791839A patent/EA201791839A1/ru unknown
- 2016-02-17 US US15/550,152 patent/US10722479B2/en active Active
- 2016-02-17 EP EP16752959.3A patent/EP3258926A4/en not_active Withdrawn
- 2016-02-17 CA CA2976229A patent/CA2976229A1/en not_active Abandoned
- 2016-02-18 TW TW105104725A patent/TW201630871A/zh unknown
- 2016-02-18 AR ARP160100435A patent/AR103728A1/es unknown
-
2017
- 2017-08-08 IL IL253901A patent/IL253901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180036260A1 (en) | 2018-02-08 |
| EP3258926A1 (en) | 2017-12-27 |
| US10722479B2 (en) | 2020-07-28 |
| CA2976229A1 (en) | 2016-08-25 |
| AR103728A1 (es) | 2017-05-31 |
| TW201630871A (zh) | 2016-09-01 |
| BR112017017673A2 (pt) | 2018-07-17 |
| MA41557A (fr) | 2017-12-26 |
| JP2018507210A (ja) | 2018-03-15 |
| WO2016133989A1 (en) | 2016-08-25 |
| EP3258926A4 (en) | 2018-11-14 |
| EA201791839A1 (ru) | 2018-02-28 |
| IL253901A0 (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003792A (es) | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| MX2022004304A (es) | Agentes inductores de apoptosis. | |
| HUE063026T2 (hu) | Eljárások és készítmények LDHA expressziójának gátlására | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| MX387625B (es) | Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| DK3684333T3 (da) | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| EA032920B1 (ru) | Способы получения соединений бензохинолина | |
| MX2020007131A (es) | Inhibidores de histona acetiltransferasa de la familia myst. | |
| TN2018000057A1 (en) | Compounds useful for inhibiting ror-gamma-t. | |
| PH12017500348A1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| WO2015179823A8 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
| FI20165932A7 (fi) | Immunomodulatorisia koostumuksia | |
| PH12017502148A1 (en) | Pharmaceutical compositions and use thereof | |
| WO2016109361A3 (en) | 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase | |
| MX2017010567A (es) | Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2. | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof | |
| WO2016019312A3 (en) | Vmat inhibitory compounds | |
| TR201620309A2 (tr) | Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇ | |
| HK1227281A1 (en) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
| IL246768A0 (en) | Benzoquinolone compounds as vmat2 inhibitors |